We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 1,709

Entitlement: Intervet Bitten by Lack of Evidence of Assignment
  • Davies Collison Cave
  • Australia
  • March 27 2017

Merial has succeeded in its patent opposition appeal to the Federal Court against the grant of Intervet's Australian Patent Application for a soft


Damages for pharmaceutical patent infringement: Federal Court gives long awaited guidance
  • Herbert Smith Freehills LLP
  • Australia
  • March 27 2017

Last week, the Federal Court handed down the important decision in Bayer Pharma Aktiengesellschaft v Generic Health Pty Ltd 2017 FCA 2501 regarding


Landmark damages decision sets new benchmark for patent infringement claims against generic companies
  • Clayton Utz
  • Australia
  • March 21 2017

The first detailed damages decision in a long time in Australia in a patent infringement claim against a generic pharmaceutical company has set a new


Federal Court of Australia dismisses preliminary discovery application regarding biosimilar suspected of infringing manufacturing process patents
  • Shelston IP Pty Ltd
  • Australia
  • March 21 2017

In the recent decision of Pfizer Ireland Pharmaceuticals v Samsung Bioepis AU Pty Ltd 2017 FCA 285 (21 March 2017), Justice Stephen Burley of the


Application to list on PBS does not constitute patent infringement per se
  • Clayton Utz
  • Australia
  • March 16 2017

The Federal Court has recently considered when an offer to supply during the term of a patent constitutes patent infringement. The Court has held


The Cost of Sufficiency
  • FB Rice
  • Australia
  • March 16 2017

In Australia, sufficiency is a requirement for patentability and goes to whether a patent specification provides adequate information to the skilled


Pharmaceuticals in South East Asia
  • FPA Patent Attorneys
  • Australia, Indonesia, Malaysia, New Zealand, Philippines, Singapore, Thailand, Vietnam
  • March 14 2017

Case law has confirmed that methods of medical treatment are patentable. ‘Swiss-style’ claims are also separately allowable


2016 - a year at a glance
  • FPA Patent Attorneys
  • Australia
  • March 14 2017

What is a human? When is your best method not good enough? When is an inventor not an inventor? What happens when your patent application fails to


Can Swiss-style claims go off-piste in Australia?
  • FPA Patent Attorneys
  • Australia
  • March 6 2017

Can Swiss-style claims go off-piste in Australia? Is it possible under Australian law for Swiss-style claims to cover the use of compounds in methods


Has “Raising the Bar” actually raised the bar on inventive step?
  • Shelston IP Pty Ltd
  • Australia
  • March 2 2017

Nearly four years ago, on 15 April 2013, Australian patent law entered a brave new world. Gone were the days of so-called "soft" patentability